AUSTIN, Texas, February 1, 2018/PRNewswire/ — Vermillion, Inc. (NASDAQ: VRML) announced today that it has been granted two new US patents that significantly expand coverage for its core technologies, OVA1™ and Overa™.
- The first, US Patent No. 9,816,995, entitled “Biomarker for ovarian cancer CTAP3- related proteins,” describes and claims panels of biomarkers associated with ovarian cancer.
- The second patent, US Patent No. 9,846,158, entitled “Predictive biomarkers for ovarian cancer,” describes and claims sets of reagents used to measure biomarkers associated with ovarian cancer.
“These two new patents are significant wins for the organization and they further build upon our strong intellectual property position surrounding ovarian cancer and pelvic mass diagnostics,” said Valerie Palmieri, President and CEO of Vermillion. “We are very excited about these new patents and the expanded coverage that they provide for tools for earlier detection, risk assessment, diagnosis and treatment planning for ovarian cancer”
Vermillion, Inc. (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company’s initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit www.vermillion.com.